
From Basel: TOLREMO Therapeutics is working on cancer resistance - the company believes is targeting CBP/p300 just stared phase 1 data at World Lung
BiotechTV - News
00:00
Blocking Cancer’s Drug-Tolerant Escape State
Stefanie Fluckiger-Mangual describes CBP as a stress modulator that helps cancer cells survive targeted therapies and acquire later resistance.
Play episode from 04:03
Transcript


